great [1%:500 mg/dL) are at risk of developing pancreatitis. A reduction in the quantity of concurrently administered lipids may be necessary to compensate for the amount of lipid in the infusion. Use is contraindicated in patients with defective lipid metabolism (eg, pathologic hyperlipidemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia). Cardiovascular effects: Systemic hypotension may occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Reflex tachycardia may occur and may result in angina or myocardial infarction in patients with obstructive coronary disease. In both situations, reduce clevidipine dose or discontinue if profound; do not treat clevidipine-induced tachycardia with beta-blockers. Rebound hypertension may occur with prolonged use in patients not transitioned to other antihypertensive therapy; monitor these patients carefully for at least 8 hours after discontinuation of infusion. Disease-related concerns: Heart failure (HF): Dihydropyridine calcium channel blockers may cause negative inotropic effects and exacerbate HF. Avoid use in patients with HF due to lack of benefit and/or worse outcomes with calcium channel blockers in general (ACCF/AHA [Yancy 2013]). Pheochromocytoma: Use in hypertension associated with pheochromocytoma has not been studied. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Other warnings/precautions: Infection risk: To limit the potential for contamination, maintain aseptic technique while handling; use within 12 hours of puncturing vial. Monitoring Parameters Blood pressure and heart rate continually during infusion and until vital signs are stable after discontinuation (Keating 2014); patients who receive prolonged infusions of clevidipine and are not transitioned to other antihypertensive therapy should be monitored for at least 8 hours after discontinuation. Consult individual institutional policies and procedures. Pregnancy Risk Factor C Pregnancy Considerations Adverse events have been observed in animal reproduction studies. Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2012). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience headache, vomiting, or nausea. Have patient report immediately to prescriber signs of kidney problems (urinary retention, hematuria, change in amount of urine passed, or weight gain), tachycardia, abnormal heartbeat, severe dizziness, passing out, vision changes, shortness of breath, excessive weight gain, or swelling of arms or legs (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients. Next Interactions Print this page Add to My Med List More about clevidipine Side Effects During Pregnancy Dosage Information Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: calcium channel blocking agents Consumer resources Clevidipine Clevidipine Intravenous (Advanced Reading) Professional resources Clevidipine Butyrate (AHFS Monograph) Other brands: Cleviprex Related treatment guides High Blood Pressure Hypertensive Emergency] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Clevidipine Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Calcium channel blocking agents Related Drugs calcium channel blocking agents amlodipine , diltiazem , Norvasc , nifedipine , verapamil , Cardizem Hypertensive Emergency hydralazine , enalapril , nifedipine , labetalol , captopril , Vasotec , Apresoline , methyldopa , Capoten , Normodyne , Trandate , nitroprusside , More... High Blood Pressure amlodipine , lisinopril , hydrochlorothiazide , furosemide , losartan , metoprolol , atenolol , Lasix , Norvasc , valsartan , More... sooner than
makes no sense Clevidipine great
EmoticonEmoticon